Beetham Thomas W.
- SEC CIK
- 0001741382
No open-market purchases or sales filed in the past year.
Current role at each company
- VRDN Viridian Therapeutics, Inc.Chief Operating Officeras of Mar 9, 2026
- DNTH Dianthus Therapeutics, Inc.See Remarksas of Dec 2, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Beetham Thomas W. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
VRDN Viridian Therapeutics, Inc.
Chief Operating Officer1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 (view filing) | Sep 27 | 3 days | Beetham Thomas W.Chief Operating Officer | PPurchase | +5.00K | $23.41 | +$117.0K | +500.0%6.00K after |
DNTH Dianthus Therapeutics, Inc.
See Remarks1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Beetham Thomas W.See Remarks | SSale | −6.10K | $6.73 | −$41.1K | −30.5%13.9K after |